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Abstract
Background: Model-based estimates of measles burden and the impact of measles-containing vaccine (MCV) are
crucial for global health priority setting. Recently, evidence from systematic reviews and database analyses have
improved our understanding of key determinants of MCV impact. We explore how representations of these
determinants affect model-based estimation of vaccination impact in ten countries with the highest measles
burden.
Methods: Using Dynamic Measles Immunisation Calculation Engine (DynaMICE), we modelled the effect of
evidence updates for five determinants of MCV impact: case-fatality risk, contact patterns, age-dependent vaccine
efficacy, the delivery of supplementary immunisation activities (SIAs) to zero-dose children, and the basic
reproduction number. We assessed the incremental vaccination impact of the first (MCV1) and second (MCV2)
doses of routine immunisation and SIAs, using metrics of total vaccine-averted cases, deaths, and disability-adjusted
life years (DALYs) over 2000–2050. We also conducted a scenario capturing the effect of COVID-19 related
disruptions on measles burden and vaccination impact.
Results: Incorporated with the updated data sources, DynaMICE projected 253 million measles cases, 3.8 million
deaths and 233 million DALYs incurred over 2000–2050 in the ten high-burden countries when MCV1, MCV2, and
SIA doses were implemented. Compared to no vaccination, MCV1 contributed to 66% reduction in cumulative
measles cases, while MCV2 and SIAs reduced this further to 90%. Among the updated determinants, shifting from
fixed to linearly-varying vaccine efficacy by age and from static to time-varying case-fatality risks had the biggest
effect on MCV impact. While varying the basic reproduction number showed a limited effect, updates on the other
four determinants together resulted in an overall reduction of vaccination impact by 0.58%, 26.2%, and 26.7% for
cases, deaths, and DALYs averted, respectively. COVID-19 related disruptions to measles vaccination are not likely to
change the influence of these determinants on MCV impact, but may lead to a 3% increase in cases over 2000–
2050.
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Conclusions: Incorporating updated evidence particularly on vaccine efficacy and case-fatality risk reduces
estimates of vaccination impact moderately, but its overall impact remains considerable. High MCV coverage
through both routine immunisation and SIAs remains essential for achieving and maintaining low incidence in high
measles burden settings.
Keywords: Measles, Vaccination impact, Transmission dynamic model, Routine vaccination, Supplementary
immunisation activity
Background
Measles is a highly contagious disease that may result in
severe morbidity and mortality, particularly in young
children and in settings with poor access to treatment.
Vaccination is a safe and effective measure for measles
prevention and control, as seen in high-income coun-
tries since its first licensure in 1961 [1]. The optimal age
range of the first dose of measles-containing vaccine
(MCV1) depends on the local variation in seasonality,
birth rate, and access to care [2]. In settings with on-
going measles transmission, the World Health
Organization (WHO) recommends delivering MCV1 to
children of 9 months old, and following up with the sec-
ond dose (MCV2) for children at 15–18 months old [3].
In addition, among countries with weak health systems,
supplementary immunisation activities (SIAs) through
vaccination campaigns are highly effective in protecting
under-immunised and zero-dose children by closing im-
munity gaps and interrupting measles transmission [3].
Vaccination contributes to the establishment of high
levels of population immunity required for measles elim-
ination, which is verified by the absence of endemic
measles transmission for at least 36 months [4]. In 2011,
the Global Measles and Rubella Strategic Plan was set
up with a goal to achieve measles elimination in at least
five WHO regions by the end of 2020 [5]. However,
coverage of MCV1 has stagnated since 2010 in many
countries and has been set back in 2020 due to routine
immunisation service disruptions and mass vaccination
campaign suspensions caused by the COVID-19 pan-
demic [6]. This has increased immunity gaps and the
risk of measles outbreaks.
Strategic investments to improve measles vaccine
coverage globally are partially informed by model-based
estimates of measles burden and the impact of vaccin-
ation. An analysis conducted by the Vaccine Impact
Modelling Consortium found that 57% of all vaccine-
related mortality reduction was due to measles vaccin-
ation in 98 low- and middle-income countries (LMICs)
between 2000 and 2019 [7]. An updated analysis for 112
LMICs found that 47 million measles deaths were esti-
mated to be averted from vaccination activities occurring
between 2000 and 2030 [8]. However, such estimates are
highly dependent on our knowledge of key determinants
of measles incidence and mortality as well as vaccination
impact. Over the past decade, there have been substan-
tial advances to our knowledge of measles case-fatality
risks (CFRs) [9], social contacts driving person-to-person
infection transmission [10, 11], age-related vaccine effi-
cacy [12], the ability of SIAs to reach zero-dose popula-
tions [13], and measles basic reproduction numbers [14].
Nonetheless, how this additional evidence on epidemio-
logical, behavioural, and programmatic determinants af-
fects estimates of vaccination impact has never been
systematically explored.
In this study, we investigated the extent to which re-
cent evidence updates about these determinants affects
model-based estimates of measles burden and vaccin-
ation impact. To do this, we used the Dynamic Measles
Immunization Calculation Engine (DynaMICE), a
population-based dynamic model of measles transmis-
sion that has been used to inform vaccination impact
[7]. We incorporated the updated data sources of these
determinants into the DynaMICE model and assessed
their individual and combined effects on the estimation




DynaMICE is an age-structured compartmental trans-
mission model designed to assess the impact of measles
vaccination globally. Susceptible individuals become in-
fected after effective contact with an infectious person
and remain immune once they recover from their infec-
tion. Infants are born with or without maternal anti-
bodies, depending on the immunity of their mothers.
The population is further divided according to their re-
ceived number of measles-containing vaccine doses (see
Fig. 1). The age structure is composed of weekly age
classes for the first 3 years of age, with annual age clas-
ses thereafter up to 100 years. The force of infection is
calculated by multiplying an age-dependent per-capita
contact rate with the total number of infectious people
in the population and the probability of transmission per
contact. The latter is calculated by scaling the next-
generation matrix to reach a target basic reproduction
number (R0) of 16, and assuming the average duration
of infectiousness is 14 days. Annual seasonality of mea-
sles transmission was also incorporated into the model
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structure. Maternal immunity was assumed to last for an
average of 6 months after birth [15], while individuals
who recover from measles disease or acquire effective
vaccine protection develop lifelong immunity. Measles
deaths are calculated by applying an age-specific CFR to
the incidence of cases. The model was coded in R and
Fortran-95, and the code is available in https://github.
com/lshtm-vimc/dynamice. Details of model equations
and parameters are included in Additional file 1: Table
S1 and Note S1, and also described in previously pub-
lished studies [7, 16].
Measles vaccination strategies
In the DynaMICE model, vaccination can be delivered
to any age or range of ages and in either routine vaccin-
ation (MCV1, MCV2) or SIAs. We assessed a range of
model parameterisations from the perspective of four
vaccination strategies: (1) no-vaccination, (2) MCV1
only, (3) MCV1 and MCV2, and (4) MCV1, MCV2, and
SIAs. We assumed that the implementation of MCV1
and MCV2 complies fully with the WHO-recommended
schedule [3], in which vaccine doses are delivered to
children aged at 39 weeks (9 months) and 72 weeks (me-
dian of 15–18 months), respectively. MCV2 is delivered
to children who have received one dose of measles vac-
cine. In addition to routine immunisation, SIAs target
children of different age groups and occur at different
intervals depending on settings. For each country, we
adopted WHO-UNICEF estimates for historical coverage
of routine immunisation [17] and calculated national
SIA coverages by the number of doses delivered and the
total number of population in a country (see Additional
file 1: Note S2) [18]. Future vaccine coverage for routine
immunisation was projected to increase by 1% per year,
up to a maximum of 95% [7], while SIAs were assumed
to take place every 3 years from the last recorded year
with the same target population and coverage (see the
following “COVID-19 related disruptions to measles vac-
cination” section and Fig. 2). We modelled vaccine effi-
cacy as all-or-nothing, that is, offering complete
protection to a defined proportion of the vaccinated
population, and no protection to the remainder of the
vaccinated population. The efficacy for the first dose was
assumed to depend on the age of vaccination (with fur-
ther explanation in the later sections), while the com-
bined first and second dose was assumed to have 98%
efficacy [19]. No additional protection was assumed to
be received from any further doses of measles vaccine,
and immunity was assumed to be lifelong.
Measles vaccination impact metrics
We modelled measles transmission and vaccination im-
pact in ten highest measles burden countries in 2000 –
India, Nigeria, Pakistan, Ethiopia, Afghanistan, Sudan,
Tanzania, Niger, Somalia, and Democratic Republic of
the Congo (DR Congo), together accounting for more
than 65% of global measles mortality in that year [20].
For each country and vaccination strategy, we projected
time trends and age distributions of measles cases,
deaths, and disability-adjusted life years (DALYs). We
estimated the number of new infections, defined as inci-
dent measles cases, over 2000–2050, to estimate the his-
torical impact of vaccination from 2000 to 2020, and to
project the potential impact that continued coverage im-
provements may have after 2020. Measles-related deaths
were calculated by multiplying the estimated number of
measles cases with the specified age-specific CFR [9, 21].
DALYs for age group a at year k in country c were fur-
ther calculated by:
DALYa;k;c ¼ ðXa;k;c−Ya;k;cÞ  ωþ Ya;k;c  La;k;c;
where Xa, k, c and Ya, k, c represent the number of cases
and deaths, respectively; ω denotes the product of dis-
ability weight [22] and length of illness, equal to 0.002;
and La, k, c denotes the remaining life expectancy at age
of death [23]. No time discounting was applied to the
DALY calculation. We also assessed the calendar year
for a country to have conditions suitable to achieve mea-
sles elimination, based on an approximate criterion—
Fig. 1 DynaMICE—Dynamic Measles Immunisation Calculation
Engine. Model structure of DynaMICE for a single age stratum is
presented. Individuals can be divided into 13 mutually exclusive
states: M-maternally immune, S-susceptible, I-infectious, R-recovered.
V1, V2, and V3 denote the received number of 1, 2, and 3 and more
vaccine doses respectively. Individuals with natural or vaccine-
acquired immunity (orange shaded squares) are not susceptible to
measles. Arrows denote the change between two states over the
transmission and progression of measles. In this model, births only
add to the youngest age group. For clarity of presentation, ageing
and death are not shown
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measles incidence has been maintained at < 1 case per
million population for at least three consecutive years [4,
24]. In assessing the key determinants of measles vaccin-
ation impact, we calculated cumulative vaccine-averted
burden over 2000–2050 by comparing the vaccination
strategies to the baseline with no vaccination.
Evaluation of determinants
We updated the data sources for five key determinants
of vaccination impact in DynaMICE: case-fatality risk,
social contact patterns, age-dependent vaccine efficacy,
proportion of zero-dose children reached by SIAs, and
basic reproduction numbers (Fig. 3). For the first four
determinants, we first modelled a ‘base’ scenario based
on previously adopted data sources [7, 16] and then al-
tered each determinant individually to reflect recent evi-
dence updates. We also evaluated a ‘full-update’ scenario
that includes all the updated data sources for four of the
determinants (Table 1) and examined the resulting
changes in measles vaccination impact. For the fifth de-
terminant, we explored a wide range of R0 values, based
on a systematic review [14] which reveals a higher
Fig. 2 Measles vaccine coverage by dose and country, 2000–2050. Historical coverage data by dose and country were obtained from the WHO
databases, while future trends were assumed to increase by 1% every year for the first (MCV1) and second (MCV2) doses delivered through
routine programmes. Supplementary immunisation activities (SIAs) were assumed to occur every 3 years in the future projection, with the
coverage seen in the most recent year. Multiple rounds of SIAs may happen within a single year in a country. Colours of lines and circles
represent different assumptions on the effect of COVID-19 related disruptions. Vertical dashed lines mark the year 2000 and the numbers next to
the lines show the absolute difference in MCV1 and MCV2 coverage estimates in the COVID-19 scenario compared to the baseline
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variability of measles transmissibility compared to what
was previously known.
Case-fatality risk
The impact of measles vaccination using two sets of glo-
bal CFR estimates was compared (Fig. 3A, and Add-
itional file 1: Figure S1): (i) an earlier review of 58
publications by Wolfson et al. [21], which provided
time-invariant CFRs for children under 5 years old in
different regions, with a further assumption that CFR
was halved for children over 5 years old [27]; and (ii) an
updated review of 124 publications by Portnoy et al. [9],
which estimated country-specific, time-varying CFRs for
children under 5 and over 5 years old, using a log-linear
model with covariates such as local measles attack rate,
under-five mortality, calendar year, and percentage of
Fig. 3 Updates for key determinants of measles vaccination. Historical and updated data sources for the four determinants are compared,
including A case-fatality risk, B social contact patterns, C age-dependent vaccine efficacy, and D SIA coverage in zero-dose population. For
country-specific assumptions like A and B, we demonstrated the data in India (the country with the highest measles mortality in 2000) and
respectively include data in other countries in Additional file 1: Figure S1 and S2
Fu et al. BMC Medicine          (2021) 19:281 Page 5 of 15
population living in urban areas. For future projection,
we assumed that CFRs remained stable at their 2018
levels over 2019–2050, in consideration of uncertain
changes in future improvements of healthcare and vac-
cination programmes as well as the potential impact
arising from the COVID-19 pandemic. The CFR esti-
mates used in this study were also used in a modelling
analysis of the impact of COVID-19 disruption to mea-
sles vaccination [6].
Social contact patterns
Our original study used the contact matrix adapted from
the POLYMOD study [25] to represent age-dependent
mixing patterns in all countries, because it showed sens-
ible characterisation of measles transmission. Since then,
several contact surveys in LMICs have been conducted;
based on these updated surveys, country-specific demo-
graphics in 2020, and the most recent data for house-
hold structure, labour force, and school enrolment,
synthetic contact matrices have been conducted for most
countries [10, 11]. With these two types of social mixing
matrices (Fig. 3B, and Additional file 1: Figure S2), we
additionally considered two simple assumptions that are
not based on empirical surveys: (i) the POLYMOD con-
tact matrix from Great Britain, (ii) synthetic country-
specific contact matrices, (iii) a matrix with contacts
proportional to the age distribution of the population,
and (iv) a uniform matrix with no age-dependency in
mixing (see Additional file 1: Note S3). All the age-
dependent matrices were normalised to reflect the
assigned scale of R0, so the model results can be prop-
erly compared.
Age-dependent vaccine efficacy
As shown in Fig. 3C, we compared two assumptions for
the age trend of first-dose vaccine efficacy: (i) a simpli-
fied step-change from 85% to 95% at a cut-off of 1 year
old [19]; and (ii) a linear increase of 1.49% for every in-
crease in month of age, derived from a recent systematic
review of 33 measles vaccine efficacy studies in measles-
endemic settings [12]. We capped the vaccine efficacy
for the first dose at 98%, which is equivalent to the level
of protection provided by two doses of MCV [19].
Proportion of zero-dose children reached by SIAs
Based on a previous exploration of the population
reached by SIAs using Demographic and Health Surveys
data for 14 countries [13], we fit a weighted logistic
function to describe the association between the SIA
coverages in total population and in zero-dose children
(Fig. 3D). We then calculated the SIA doses given to the
population with previous vaccination history (see
Table 1 Scenarios for evidence updates of key determinants of measles vaccination impact. Assumptions for four key determinants
used in each scenario and their data sources are summarised. Abbreviations: CFR case-fatality risk, SIA supplementary immunisation
activity
Scenarios Data sources and assumptions for determinants
Base With data sources used previously [7, 16]:
• CFRs: country-specific, time-invariant estimates for under 5 years old from Wolfson
[21] and halving such estimates for older than 5 years old.
• Contact patterns: physical contact matrix from POLYMOD Great Britain [25].
• Age-dependent first-dose vaccine efficacy: step function which assumes 85% for
under one year old and 95% for over 1 year old [19].
• SIA coverage in zero-dose population: equal coverage in population with or with-
out previous vaccination (random distribution of SIA doses).
(A) CFR, Portnoy’s method ‘Base’ scenario, with updated CFRs: country-specific, time-varying, incidence-related
estimates for under and over 5 years old from Portnoy et al. [9]
(B) Contact patterns, synthetic matrices ‘Base’ scenario, with update for contact patterns: country-specific synthetic matrices
[10, 11]
(B’) Contact patterns, proportional mixing ‘Base’ scenario, with contact probabilities proportional to the age distribution of
population
(B”) Contact pattern, uniform mixing ‘Base’ scenario, with uniform contact probabilities across age groups
(C) Age-dependent first-dose vaccine efficacy, linear trend ‘Base’ scenario, with updated first-dose vaccine efficacy: efficacy as a linear function
of age with an increase of 1.49% per month of age, from 68% at birth to 98% at
highest [12]
(D) SIA coverage in zero-dose population, dependency on
previous vaccination
‘Base’ scenario, with update for SIA coverage in zero-dose population: informed by a
weighted logistic function fitted to all available surveys [13]
(D’) SIA coverage in zero-dose population, dependency on
previous vaccination, excluding the largest survey
‘Base’ scenario, with update for SIA coverage in zero-dose population: informed by a
weighted logistic function fitted to available surveys except for the one with the lar-
gest sample size (Indonesia, 2002) [13]
(D”) SIA coverage in zero-dose population, 7.7% never
reached
‘Base’ scenario, with random delivery of SIA doses except for an isolated 7.7% of the
target population that are assumed to never receive any measles vaccine dose [26]
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Additional file 1: Note S1), by subtracting those doses
received by zero-dose population from the total doses
reported in the WHO data [18]. We compared this asso-
ciation to a random distribution of SIA doses in the
‘base’ scenario, where SIA doses are delivered to the tar-
get population regardless of their measles vaccination
history. To assess the robustness of the weighted logistic
function in representing the delivery of SIA, we refitted
the function after excluding the survey with the largest
sample size (also the oldest survey in the dataset), and
then evaluated the vaccination impact. In addition, we
assessed an alternative assumption that 7.7% of children
are never reached by SIAs while the rest of the popula-
tion are given SIAs randomly, using an approximation
based on the prevalence of children who had not re-
ceived any dose of MCV and other three essential child-
hood vaccines in a recent analysis [26].
Basic reproduction number
We assumed an R0 of 16 in the main analysis, according
to a systematic review that included studies in LMICs in
the vaccine era [14]. We further examined measles bur-
den and vaccination impact with R0 values of 12, 20, and
24, to address the right-skewed distribution of estimates
observed in the review [14].
COVID-19 related disruptions to measles vaccination
In 2020, the WHO-UNICEF estimates report an abso-
lute change in MCV1 and MCV2 coverages from − 6%
to 5% (compared to 2019) across different countries
[17], where the country variation is likely due to a mixed
effect of COVID-19 service disruptions and ongoing ef-
forts for immunisation programme expansion. To
understand the potential effect of the COVID-19 disrup-
tions on measles burden and vaccination impact, we ex-
amined two vaccine coverage scenarios (see Fig. 2):
(i) a ‘Non-COVID-19 scenario’ as the base case,
considering there is still great uncertainty around
how the impact of COVID-19 disruptions will last
and how immunisation programmes will resume.
Without COVID-19 disruptions, we assumed a 1%
absolute coverage increase a year from 2019 and up
to 95%, based on WHO-UNICEF routine coverage
figures. For countries reporting a growth in the
coverage estimates from 2019 to 2020, we took the
2020 estimates and assumed the annual 1% cover-
age increase to begin from 2020. SIAs are assumed
to proceed as planned in 2020 for six countries
(India, Nigeria, Ethiopia, Tanzania, Somalia, and DR
Congo), with either their actual coverage in 2020 (if
the SIA did indeed happen), or the coverage of the
most recent SIA for similar target group and
purpose in that country (if the SIA did not happen)
[18].
(ii) a ‘COVID-19 scenario’ based on the 2020 WHO-
UNICEF routine coverage estimates [17]. In 2021
and 2022, routine coverage in each country is as-
sumed to return to its 2020 level in the ‘Non-
COVID-19’ scenario [28]. The expansion for rou-
tine immunisation programme by 1% absolute
coverage increase a year is delayed to 2023. For
campaign vaccination, COVID-19 disruptions led to
the cancellation of SIAs in India and Nigeria, two of
the six countries planned for SIAs in 2020 [18], but
future SIAs are assumed to be unaffected.
In addition, we assumed that measles CFRs are the
same in both scenarios and are estimated using measles
incidence and vaccine coverage in the ‘Non-COVID-19’
scenario. While the decline in vaccine coverage and ex-
cess measles incidence in the ‘COVID-19’ scenario are
associated with increased measles CFR estimates, the
relative increase was estimated to be less than 1%, ac-
cording to the prediction model applied in Portnoy’s
CFR estimates [9].
Results
Figure 4 shows model projections of annual measles in-
cidence over 2000–2050 under different vaccination
strategies in India, Nigeria, Pakistan, Ethiopia, and other
six high-burden counties in the ‘full-update’ scenario
that uses the most recent evidence for four determinants
of vaccination impact and assumes no COVID-19 re-
lated disruptions. Under the implementation of MCV1,
MCV2, and SIAs, 253 million measles cases, 3.8 million
deaths, and 233 million DALYs are projected over the
51 years in the ten countries. In the COVID-19 scenario,
an additional 7.1 million cases, 109 thousand deaths, and
6.7 million DALYs are projected over 2000–2050, corre-
sponding to a nearly 3% increase in measles burden
(Table 2). Among the top ten high-burden countries,
India contributes the most to overall measles cases (47%
with no vaccination) but a smaller proportion of overall
deaths (26% with no vaccination), because of its rela-
tively low CFR compared to other countries (see Add-
itional file 1: Figure S1) [9].
Model results show the important roles of routine im-
munisation and SIAs in measles control. Of these vac-
cination activities, the first dose provided through
routine programmes (MCV1) contributes the most to
burden reduction. Based on the ‘full-update’ model, cu-
mulative measles cases over 2000–2050 are projected to
reduce by 66% with MCV1 alone, 78% with a second
routine dose (MCV1 and MCV2), and 90% with further
inclusion of supplementary doses (MCV1, MCV2, and
SIAs). The incremental impact of MCV2 and SIA doses
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is not as large as MCV1 but essential in maintaining a
low level of measles transmission and preventing the
periodical occurrence of large outbreaks as the number
of susceptibles accumulates. Measles incidence is pro-
jected to be less than one case per million for at least
three consecutive years by 2050 in Pakistan, Ethiopia,
Sudan, and Niger, with high coverage of both MCV2
and SIA doses (see Additional file 2: Table S2). A low
level of measles incidence could still be attained by ei-
ther a high MCV2 coverage (India, Tanzania) or a high
SIA coverage (Nigeria, Afghanistan), where the two vac-
cination activities could compensate for the performance


































Country India Nigeria Pakistan Ethiopia Other 6 countries
Fig. 4 Measles vaccination impact by calendar year. Measles cases, deaths, and disability-adjusted life years by vaccination strategies and
countries are presented based on the model results of the ‘full-update’ scenario that includes all the updates of key determinants. In India,
Nigeria, Pakistan, Ethiopia, and other 6 countries (Afghanistan, Sudan, Tanzania, Niger, Somalia, DR Congo) with high measles burden, a
substantial reduction of measles burden can be attributed to MCV1, while MCV2 and SIAs contribute to the maintenance of low-level measles
transmission. Abbreviations: MCV1 first routine dose of measles-containing vaccine, MCV2 second routine dose of measles-containing vaccine, SIAs
supplementary immunisation activities
Table 2 COVID-19-related disruptions to measles burden and vaccination impact. Total burden (cases, deaths, and DALYs) and
vaccine impact (cases, deaths, and DALYs averted) in ten high measles burden countries over 2000–2050 are presented, based on
coverage estimates without and with disruptions caused by COVID-19. Proportionate changes due to COVID-19 disruptions are
shown in parentheses. Model scenarios in this analysis were conducted under the ‘full-update’ model, with the assumption of R0 =
16 and implementation of MCV1, MCV2, and SIA. Abbreviations: DALY disability-adjusted life years, MCV1 first routine dose of
measles-containing vaccine, MCV2 second routine dose of measles-containing vaccine, SIA supplementary immunisation activity
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of each other. Conversely, Somalia and DR Congo are
not likely to maintain this low level of measles incidence
prior to 2050, due to their limited coverages of MCV1,
MCV2 and SIA doses.
Table 3 presents model estimates of vaccination im-
pact in terms of total averted cases, deaths, and DALYs
over 2000–2050 in the scenarios listed in Table 1 for
assessing updated evidence sources. Using the updated
CFR estimates from Portnoy’s review instead of Wolf-
son’s review is the most influential single change, result-
ing in 17.0–22.9% reduction in averted deaths and
DALYs. Using contact patterns from synthetic matrices
or the POLYMOD Great Britain matrix results in similar
estimates of vaccine-averted cases and deaths, lying
within 3.2% of each other. Under the assumptions of
proportional and uniform mixing patterns, the total
number of vaccine-averted cases is similar to the esti-
mate based on the POLYMOD matrix. However, the as-
sumptions of uniform mixing and proportional mixing
result in a 22.9–26.0% and 7.3–9.6% reduction in the
number of averted deaths, respectively, due to the in-
crease in the mean age of measles infection and death
(Fig. 5). Applying a linear trend in vaccine efficacy by
age instead of a step function results in a 2.0–10.4% de-
cline in averted cases, depending on the vaccination
strategy. In comparison to random delivery of SIA doses,
the weak dependency between SIA doses and previous
vaccination status is projected to produce a small in-
crease in averted cases (0.26–0.40%), using either of the
logistic functions derived from previous surveys. Never-
theless, a 6.1% reduction in vaccine-averted cases is pro-
jected when assuming that 7.7% of children are never
reached by SIAs, where there are fewer zero-dose chil-
dren being benefited from SIA protection (see Add-
itional file 2: Figure S3). Overall, the evidence updates
about the CFR estimates and age trend in first-dose vac-
cine efficacy have the largest influence on MCV impact.
The combined effect of all these evidence updates
(‘full-update’ scenario) is a decline in vaccine-averted
burden, with a 0.58–8.7% reduction in cases averted, and
Table 3 Averted measles cases, deaths, and DALYs by vaccination strategies and evaluation scenarios. Total vaccine-averted burden
in ten high measles burden countries over 2000–2050 is presented, with proportionate change from the ‘base’ scenario shown in
parentheses. All model scenarios were conducted under the assumption of R0 = 16. Details of data sources for key determinants
assumed for each scenario can be found in Table 1. Abbreviations: CFR case-fatality risk, DALY disability-adjusted life years, MCV1 first
routine dose of measles-containing vaccine, MCV2 second routine dose of measles-containing vaccine, SIA supplementary
immunisation activity








































































































































(D) SIA delivery to zero-dose population, dependency
on previous vaccination









(D’) SIA delivery to zero-dose population, dependency
on previous vaccination, excluding the largest survey









(D”) SIA delivery to zero-dose population, 7.7% never
reached
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a 24.2–26.7% reduction in deaths and DALYs averted
(Table 3). However, similar measles burden trends are
seen using the ‘base’ and ‘full-update’ models, both with
a fast decline in measles cases following the country-
specific rollout of routine immunisation and SIAs (see
Additional file 2: Figure S4). Country schedule for reach-
ing and maintaining a low level of measles transmission
is also similar (see Additional file 2: Table S2). In
addition, there are no significant differences in how the
updated determinants affect MCV impact between the
base case and COVID-19 scenarios, although the total
number of vaccine-averted cases is projected to be
smaller in the COVID-19 scenario (see Table 2, and
Additional file 2: Table S4).
Next, we compare the age distribution of cumulative
measles cases over 2000–2050 under different assump-
tions for contact patterns. Figure 5 presents the propor-
tions of measles cases from 0 (first year of life), 1, 2, and
3 years and above of age in India, Nigeria, Pakistan,
Ethiopia, and other six high-burden countries. Similar
age distributions of measles cases are shown across
countries. The update with country-specific synthetic
matrices results in an older average age of measles cases,
compared to the POLYMOD matrix. The age distribu-
tion of measles cases is least concentrated in younger
age groups under the assumption of uniform mixing.
Without the implementation of vaccination, the propor-
tions of cases older than 3 years old in each country are






























































Fig. 5 Age distribution of cumulative measles cases over 2000–2050 by different contact patterns. Proportions of measles cases aged 0, 1, 2, and
3+ years in India, Nigeria, Pakistan, Ethiopia, and other 6 countries (Afghanistan, Sudan, Tanzania, Niger, Somalia, DR Congo) with high measles
burden are presented, by the assumptions of uniform mixing, proportional mixing, POLYMOD Great Britain contact matrix, and country-specific
synthetic contact matrices. Compared to uniform mixing, contact patterns that consider age-related mixing tend to result in a lower average age
at infection. Based on the POLYMOD matrix, the projected cases are more concentrated in younger age groups compared to the other contact
patterns. Abbreviations: MCV1 first routine dose of measles-containing vaccine, MCV2 second routine dose of measles-containing vaccine, SIAs
supplementary immunisation activities
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16–17% with the POLYMOD matrix, 20–32% with syn-
thetic matrices, 22–51% with proportional mixing, and
62–68% with uniform mixing. The increase in the mean
age under the assumption of uniform mixing accounts
for the reduced vaccination impact against deaths, since
older measles cases are at a lower risk of death (see Add-
itional file 1: Figure S1), even though there are more
cases prevented by vaccination (Table 3). We also ob-
serve a shift towards an older average age at infection in
any of the measles vaccination strategies, compared to
the model results assuming no vaccination.
Figure 6 presents the absolute measles burden and
vaccination impact over the evaluation period by dif-
ferent values of R0 in the ‘full-update’ scenario. A
larger value of R0 led to a higher estimate of measles
burden but a smaller vaccination impact. However,
the overall impact of R0 is limited, with less than 5%
of variation in vaccine-averted cases and deaths
compared to the baseline R0. Increased burden
driven by a larger R0 also delays the achievement of
measles elimination, in particular for countries with-
out high national coverage of SIAs (Additional file 2:
Table S2). Nevertheless, our findings about the sub-
stantial contribution of measles vaccination and the
relative impact of MCV1, MCV2 and SIA doses re-
main unchanged.
Discussion
Using the DynaMICE model, we have considered the
best available updated evidence and explored the influ-
ence of recent systematic reviews and database analyses
on key determinants of measles vaccination impact:
case-fatality risk, social contact patterns, age-dependent
vaccine efficacy, proportion of zero-dose children
reached by SIAs, and basic reproduction numbers. With



















































































































































































Fig. 6 Cumulative measles burden over 2000–2050 by vaccination strategies and R0. The total number of cases, deaths, and DALYs (upper panel)
and corresponding averted proportions (lower panel) in the four countries are compared by different values of R0. Despite the variability of R0,
there is a limited effect on the vaccine impact estimates. Abbreviations: DALY disability-adjusted life years, MCV1 first routine dose of measles-
containing vaccine, MCV2 second routine dose of measles-containing vaccine, SIAs supplementary immunisation activities
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vaccination impact marginally for cases averted and sub-
stantially for deaths and DALYs averted. As before, we
find that the first vaccine dose delivered by routine im-
munisation programmes contributes to the largest re-
duction of measles burden, but the second routine dose
and supplementary doses also provide important incre-
mental benefits towards elimination. We find that up-
dates to two of the determinants have the biggest
changes in the vaccination impact: making the first-dose
vaccine efficacy a linearly age-dependent function based
on a recent review [12] decreases impact estimates by
2–10%, while using time-dependent and incidence-
related CFRs [9] decreases them by 17–23%. Updated
contact patterns, SIA dependency on previous vaccin-
ation history, and the basic reproduction number make
relatively little difference to vaccination impact esti-
mates. Overall, measles vaccination impact remains sub-
stantial despite these data updates, although the impact
is relatively reduced when COVID-19-related disrup-
tions are considered.
In the ten countries with the highest measles mortality
in 2000, our model projections show varying trends of
measles incidence under the vaccination strategy involv-
ing MCV1, MCV2 and SIAs doses. In Nigeria, Somalia,
and DR Congo, measles transmission is projected to be
suppressed for a few years followed by resurgence (see
Additional file 2: Table S2). The difficulties faced by
these countries result from having a lower coverage of
routine immunisation (both MCV1 and MCV2) com-
pared to the other countries, and their SIAs are not
highly effective to close the measles immunity gaps (see
Fig. 2). We did not model the possibility of measles
elimination directly, since this would require consider-
ation of case importation, contact tracing, and outbreak
response, which are not captured by aggregate compart-
mental models like DynaMICE. However, the low mea-
sles incidence achieved by countries like India suggests
that the measles elimination schedules aimed by the
WHO regional office [29] may be possible if high cover-
age of both routine and campaign vaccination activities
can be maintained in the long run (Additional file 2:
Table S2, Figure S5 and S6).
Updating CFR estimates is the single most influential
change among the determinants that we evaluated. The
updated Portnoy’s CFRs start higher than Wolfson’s
CFRs in 2000 but then decline (Additional file 1: Figure
S1), whereas Wolfson’s CFRs are assumed to be time-
invariant. Across the ten high-burden countries, a 17–
23% reduction is seen in cumulative vaccine-averted
deaths and DALYs over 2000–2050 with updated CFRs.
Additionally, with MCV2 and SIA doses included in the
vaccination strategy, the averted measles burden is pro-
jected to increase as a result of a relatively larger decline
in Portnoy’s CFRs (Additional file 1: Figure S1).
Referring to the log-linear model used for estimating
CFRs in Portnoy’s method [9], we found measles attack
rate, one of the covariates which can be largely reduced
by vaccination, may explain the different levels of reduc-
tion in vaccination impact across vaccination strategies.
Considering the importance of CFRs to estimates of
measles burden and vaccination impact, understanding
how CFRs may change in the future needs to be a key
future research priority. In addition to case fatality, ex-
ploring the temporal variation in case severity and dis-
ability weight will improve the estimation of the measles
disease burden.
The relationship between the first-dose vaccine effi-
cacy and age at vaccination is another important deter-
minant of MCV impact. According to the updated linear
function [12], MCV1 given to children of 9 months old
shows 78% efficacy, while 85% is assumed based on the
step function used previously [19] (Fig. 3C). This update
thus reduces our estimates of MCV1 impact; neverthe-
less, since the first-dose efficacy increases with age, SIAs
that reach zero-dose population of an older age result in
increased protection, which can partly offset the reduc-
tion in MCV1 protection (Table 3). This association be-
tween vaccine efficacy and age at vaccination will be
useful for planning immunisation programmes, when
combined with local epidemiology of measles transmis-
sion to maximise the MCV impact.
Like previous modelling studies [30, 31], our analysis
shows the importance of age-dependent contact patterns
in determining measles transmission and the impact of
control strategies. Despite a small difference in the vac-
cination impact on preventing measles cases, a 23–26%
reduction in deaths averted is projected under the as-
sumption of uniform mixing, compared to the POLY-
MOD matrix (Table 1), due to the increase in the
average age at measles infection (Fig. 5). Compared to
uniform mixing, proportional mixing also relates to
measles cases of a younger age, reflecting the age com-
position of local demographics that consists of a larger
proportion of children in most high measles burden set-
tings. On the other hand, there is little difference in
model results between using the POLYMOD Great Brit-
ain matrix [25] and country-specific synthetic matrices
[11]. Both matrices capture the main pattern of age-
assortative mixing and thus led to similar estimates of
vaccination impact. The slight difference in age distribu-
tion of measles cases could be attributed to the higher
degree of age-assortativity in the POLYMOD Great Brit-
ain matrix (Additional file 1: Figure S2), which might be
less representative of LMICs with more frequent contact
between different age groups.
The proportion of zero-dose reached by SIAs is posi-
tively associated with the vaccine impact estimate be-
cause the efficacy of the first MCV dose is higher than
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the incremental protection of the second or further
doses for already-vaccinated children. However, when
countries reach a high MCV1 coverage and contain a
small size of zero-dose children, the estimation of vac-
cine impact is less sensitive to the assumption of SIA de-
pendency on vaccination status. This may partly explain
the small MCV impact seen in the update on the pro-
portion of zero-dose reached by SIAs (Table 3). There is
also remaining uncertainty around the delivery of SIA
doses. The fitted logistic function adopted in the update
analysis indicates that zero-dose children are more likely
to be reached when the coverage in the total population
is between 50 and 85% (Fig. 3D), although the depend-
ency is weak and the delivery of SIA doses is nearly ran-
dom. However, this evidence update is based on surveys
conducted during 2002–2008 [13], and more recent SIAs
may have been better able to address subnational in-
equalities in vaccination coverage, e.g., by targeting rural
areas or hard-to-reach populations [32]. There is also a
lack of representativeness of geographical diversity, since
those survey data were collected in 14 countries and
might not include marginalised populations who are
likely to have limited access to measles vaccination [13].
Thus, it is possible that a concerning fraction of children
have been missed by both routine immunisation pro-
grammes and SIAs [26]. We evaluated this possibility in
an alternative scenario with 7.7% of children never
reached by SIAs and found a significant reduction in
vaccination impact compared to random delivery (see
Additional file 2: Figure S4). The ability of reaching
zero-dose populations through SIAs has crucial implica-
tions for estimating MCV impact and planning immun-
isation activities, and therefore requires further research
to clarify.
Our results present a substantial decline in measles
cases and deaths over 2000–2019 in ten high-burden
countries. The country rank of measles mortality in
2019 has changed and India is no longer the country
with the highest burden (Additional file 2: Table S2).
The same overall trends (declining burden over time)
are seen in model-based estimates of measles incidence
over the same period from Global Burden of Diseases
2019 by the Institute for Health Metrics and Evaluation
(IHME) [20], although our results show lower absolute
incidence estimates over time (see Additional file 2: Fig-
ure S5). The difference in the incidence estimates may
stem from different approaches used in the two models.
DynaMICE is a mechanistic SIR transmission model
which translates vaccine coverage into measles incidence
using age-dependent contact data. In contrast, IHME
uses a statistical model which estimates measles inci-
dence with covariates including MCV1, MCV2 and SIA
coverage estimates, based on an assumption of additive
effects [33]. Consequently, DynaMICE may
underestimate measles incidence at high levels of routine
and SIA coverage, when the majority of targeted age
groups may be vaccinated with at least one dose. Fur-
thermore, we compared the model outputs to the WHO
case notifications provided by country health depart-
ments [34]. In Pakistan, Sudan, and Niger, our model es-
timates suggested that country-specific measles
incidence is maintained below one per million prior to
2020 (Additional file 2: Table S2), while there were more
than 2,000 cases notified in 2019. The inconsistency be-
tween model estimates and notification data at very low
levels of incidence may be associated with outbreaks re-
lated to heterogeneous MCV coverage at the subnational
level [32, 35], which are not precisely captured by a
model based on national averages of vaccine coverage.
Additionally, measles notification data need to be inter-
preted carefully, as these data may be affected by under-
reporting and time-dependent biases due to varying
surveillance and diagnostic capacity [27].
Our analysis has some limitations. First, we acknow-
ledge that vaccine coverage forecasts in both ‘Non-
COVID-19’ and ‘COVID-19’ scenarios are speculative,
because there is no way to predict future events that
may lead to disruptions to MCV coverage (such as civil
unrest or vaccine confidence crises). Second, we as-
sumed that MCV1 is delivered promptly to children at 9
months old, which assumes perfect timeliness of the
routine immunisation programme schedule. This as-
sumption of perfect timeliness may not be realistic in
most settings, where many children receive MCV1 earl-
ier, or more likely, later than the targeted age [36]. Thus,
setting-specific data on the precise age at vaccination
could provide further insight into vaccination impact.
Third, we assumed the same R0 across countries due to
a lack of systematic data for estimating the country-
specific transmissibility. Combining with the age-
dependent contact patterns, measles models fitted to
data on incidence and serology may be helpful to esti-
mate the force of measles infection in each country [31].
Nonetheless, our model findings remain robust and use-
ful, as we found in sensitivity analyses that the variations
in R0 within the range 12–24 do not substantially affect
the vaccination impact (Fig. 6). Fourth, we did not con-
sider importation of measles cases from migration,
which can be a major source of local outbreaks when
domestic measles transmission has been largely elimi-
nated [37]. Additionally, we assumed that vaccine cover-
age was uniform over the entire country. However, the
countries we modelled all have subnational regions with
substantially lower coverage than average, and which
therefore sustain measles transmission even when it is
eliminated in the rest of the country. Finally, while we
recommend incorporating these evidence updates into
measles models in the future analysis, uncertainties in
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the quality and model representation of the collected
evidence should not be overlooked. For example, in our
analysis, contact pattern was adjusted only for varying
demographics over 2000–2050 (see Additional file 1:
Note S2), while temporal changes in societal and behav-
ioural factors were not considered because of the lack of
longitudinal surveys and data. As more data and evi-
dence on the key determinants of vaccination impacts
are available, an updated review and data synthesis will
be required.
Conclusions
Recent advances in data and research have provided a
better understanding of measles transmission and vac-
cination impact. Using the DynaMICE model, we have
systematically assessed updates on the key determinants
of measles epidemiology and vaccination in ten coun-
tries with historical high measles mortality. We identi-
fied that measles vaccination impact is sensitive to the
assumptions on CFR and age-dependent vaccine efficacy
and reassure the importance of age-dependent social
contact structure. However, as we have demonstrated in
this study, these evidence updates would not undermine
the substantial contribution of measles vaccination. High
coverage of both measles vaccine doses, either through
routine or SIA vaccine delivery, is essential for meeting
and maintaining the goals for measles elimination.
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